Generated September 19, 2026.
Overview
These three securities offer markedly different angles on healthcare investing. ARKG is an actively managed ETF betting on genomic innovation and gene-editing platforms. HLTH is a newer active fund focused on AI applications across drug discovery, diagnostics, and healthcare IT. XLV is a broad sector index fund tracking the S&P 500 Health Care Select Sector, encompassing pharmaceuticals, medical devices, healthcare services, and established insurers. The key distinction: ARKG and HLTH chase high-growth, early-stage disruption; XLV provides diversified exposure to the mature healthcare establishment.
How they differ
ARKG and HLTH are both actively managed and charge 0.75% expense ratios, but they pursue different innovation vectors. ARKG focuses exclusively on genomics and molecular diagnostics—a narrower, more concentrated thesis—while HLTH casts a wider net across healthcare AI applications. The biggest structural difference is passive versus active: XLV tracks an index at 0.08% with $43.4B, while ARKG holds $1.93B and HLTH holds just $8.67M. Volatility also separates them: ARKG carries a beta of 2.37, while XLV's 0.52 reflects the lower volatility of large-cap, established healthcare.
Who each is best for
- ARKG: Fits investors pursuing concentrated exposure to genomic and gene-therapy innovation with a high risk tolerance and a multi-year time horizon; those convinced that CRISPR and molecular diagnostics will drive outsized returns relative to broader healthcare.
- HLTH: Designed for investors focused on the intersection of AI and healthcare delivery, willing to accept early-stage fund size and emerging-fund risk in exchange for thematic exposure to machine learning in diagnostics and drug discovery.
- XLV: Matches investors seeking core healthcare sector allocation with minimal fees and tax drag, including established pharma, device makers, and insurers; those prioritizing stability, income, and broad sector participation over disruptive growth.
Key risks to know
- Concentration risk in nascent themes. ARKG and HLTH both bet on emerging innovation areas with limited historical data. If genomic or healthcare AI adoption stalls or faces regulatory headwinds, these concentrated portfolios could underperform for extended periods.
- High volatility without income cushion. ARKG's beta of 2.37 signals substantial market swings relative to the broad market. Neither ARKG nor HLTH pays a dividend to offset portfolio drawdowns, leaving investors absorbing full volatility in corrections. Small asset bases invite higher tracking error, potential forced redemptions if inflows don't materialize, and wider bid-ask spreads than established peers.
- Sector cyclicality in XLV. Healthcare is more economically sensitive than its "defensive" label suggests. Rising interest rates, wage pressure in medical services, and drug pricing pressure can compress valuations across the index.
Bottom line
If you want surgical exposure to genomic disruption, ARKG offers a focused bet; if you're drawn to AI in healthcare specifically, HLTH provides thematic targeting despite its nascent size. If you seek diversified healthcare sector income with minimal cost and established liquidity, XLV serves that allocation need. All three carry distinct risk profiles, and overlaps in holdings are possible—verify before combining them. Past performance does not predict future returns.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
